Okubo, S., Kurebayashi, J., Otsuki, T., Yamamoto, Y., Tanaka, K., & Sonoo, H. (2004). Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Nature Publishing Group.

Okubo, S., J. Kurebayashi, T. Otsuki, Y. Yamamoto, K. Tanaka, and H. Sonoo. Additive Antitumour Effect of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib (Iressa, ZD1839) and the Antioestrogen Fulvestrant (Faslodex, ICI 182,780) in Breast Cancer Cells. Nature Publishing Group, 2004.

Okubo, S., et al. Additive Antitumour Effect of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib (Iressa, ZD1839) and the Antioestrogen Fulvestrant (Faslodex, ICI 182,780) in Breast Cancer Cells. Nature Publishing Group, 2004.